Crescent Diagnostics is developing a new prognostic marker for fracture risk which will make a simple to use test available to primary care physicians.

The new Bone Quality Test (BQT^®) will enable earlier identification and treatment of women at risk in the primary care environment where the need is greatest.

• Under-diagnosis is a major problem in osteoporosis today with just 12-24% of at-risk women tested in the US today
• The health economic cost of the 294,000 hip fractures in the US in 2005 was $6bn
• ¹Hip fracture is the most serious kind of fracture and has worse Disability Adjusted Life Years (DALYs) figures than many cancers including breast cancer
• ²More than 60m women over 50 are at risk in the US alone

Latest News

11th January 2010
Crescent will present at the Medtech investing forum on the 18th February 2010 in Lausanne.

23rd December 2009
Crescent awarded UK Patent for novel instrument design.